))
The difficulty in comparing SARS-CoV2 vaccines
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on February 27, 2024 05:11 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 333582416 series 3368689
Content provided by Tim Pilcher. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Tim Pilcher or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Further reading/resources:
- Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines (JAMA Network)
- SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn (American College of Cardiology)
- Handicapping the COVID Vaccine Horse Race (Medscape)
- New COVID-19 vaccine trials starting in children (MSN)
- Pfizer says its Covid vaccine trial for kids ages 12 to 15 is fully enrolled (CNBC)
- South Africa Halts AstraZeneca Vaccine Rollout Over Effectiveness Doubts With New Variant (Slate)
171 episodes
Share
